Bryan F Vaca-Cartagena, Fernanda Mesa-Chavez, Ana S Ferrigno Guajardo, Hatem A Azim, Federico Rotolo, Alejandra Platas, Alan Fonseca, Marlid Cruz-Ramos, Ana Rodriguez, Alejandro Mohar, Cynthia Villarreal-Garza
{"title":"评估年轻乳腺癌女性患者乳腺癌相关生活质量的变化:来自多中心前瞻性队列的长期结果","authors":"Bryan F Vaca-Cartagena, Fernanda Mesa-Chavez, Ana S Ferrigno Guajardo, Hatem A Azim, Federico Rotolo, Alejandra Platas, Alan Fonseca, Marlid Cruz-Ramos, Ana Rodriguez, Alejandro Mohar, Cynthia Villarreal-Garza","doi":"10.1177/17588359251337493","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Young women with breast cancer (YWBC) typically undergo intensive treatment that negatively impacts their quality of life (QoL). However, limited information is available on how their QoL changes, as most research has focused on older patients.</p><p><strong>Objectives: </strong>To assess changes in QoL among YWBC, identify the most affected QoL domains, and identify the factors associated with these changes.</p><p><strong>Design: </strong>Joven & Fuerte is a multicenter cohort of women aged ⩽40 in Mexico with newly diagnosed BC from 2014 to 2020.</p><p><strong>Methods: </strong>Participants completed the European Organization for Research and Treatment of Cancer Breast Cancer module QLQ-BR23 questionnaire at five different time points from enrollment until year 5 postdiagnosis. Clinical and treatment data were also collected. Group-based multivariate trajectory modeling was used to analyze longitudinal changes across QoL domains and classify patients into appropriate groups. Logistic models were then employed to identify associations between variables and group classification.</p><p><strong>Results: </strong>A total of 477 women (median age: 36 years; interquartile range 32-38) were included. Most had public health insurance (87%) and were diagnosed with stage II (49%) or III (39%) BC. Two trajectory groups, namely, \"good\" and \"poor,\" were identified based on QLQ-BR23 scores. Most patients (<i>n</i> = 294, 62%) were in the poor group. In the good group, sexual enjoyment scores remained stable from baseline to year 5 (51.4), whereas those in the poor group decreased (51.0-37.3). Distress related to hair loss over time declined, with scores decreasing from 36.3 to 27.0 in the good trajectory group and from 43.4 to 31.2 in the poor trajectory group. For future perspective, the good group improved from 56.4 to 79.0, while the poor group increased from 39.3 to 57.2. Patients with human epidermal growth factor receptor 2-positive BC (adjusted odds ratio (aOR) = 0.57, 95% confidence interval (CI) 0.35-0.94, <i>p</i> = 0.028) and those with public health insurance (aOR = 0.41, 95% CI 0.16-0.90, <i>p</i> = 0.035) were less likely to belong to the poor trajectory group.</p><p><strong>Conclusion: </strong>A high proportion of YWBC experience a poor QoL trajectory over time, particularly in areas related to sexual health, future perspective, and hair loss.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"17 ","pages":"17588359251337493"},"PeriodicalIF":4.3000,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084701/pdf/","citationCount":"0","resultStr":"{\"title\":\"Evaluating changes in the breast cancer-related quality of life of young women with breast cancer: long-term results from a multicenter prospective cohort.\",\"authors\":\"Bryan F Vaca-Cartagena, Fernanda Mesa-Chavez, Ana S Ferrigno Guajardo, Hatem A Azim, Federico Rotolo, Alejandra Platas, Alan Fonseca, Marlid Cruz-Ramos, Ana Rodriguez, Alejandro Mohar, Cynthia Villarreal-Garza\",\"doi\":\"10.1177/17588359251337493\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Young women with breast cancer (YWBC) typically undergo intensive treatment that negatively impacts their quality of life (QoL). However, limited information is available on how their QoL changes, as most research has focused on older patients.</p><p><strong>Objectives: </strong>To assess changes in QoL among YWBC, identify the most affected QoL domains, and identify the factors associated with these changes.</p><p><strong>Design: </strong>Joven & Fuerte is a multicenter cohort of women aged ⩽40 in Mexico with newly diagnosed BC from 2014 to 2020.</p><p><strong>Methods: </strong>Participants completed the European Organization for Research and Treatment of Cancer Breast Cancer module QLQ-BR23 questionnaire at five different time points from enrollment until year 5 postdiagnosis. Clinical and treatment data were also collected. Group-based multivariate trajectory modeling was used to analyze longitudinal changes across QoL domains and classify patients into appropriate groups. Logistic models were then employed to identify associations between variables and group classification.</p><p><strong>Results: </strong>A total of 477 women (median age: 36 years; interquartile range 32-38) were included. Most had public health insurance (87%) and were diagnosed with stage II (49%) or III (39%) BC. Two trajectory groups, namely, \\\"good\\\" and \\\"poor,\\\" were identified based on QLQ-BR23 scores. Most patients (<i>n</i> = 294, 62%) were in the poor group. In the good group, sexual enjoyment scores remained stable from baseline to year 5 (51.4), whereas those in the poor group decreased (51.0-37.3). Distress related to hair loss over time declined, with scores decreasing from 36.3 to 27.0 in the good trajectory group and from 43.4 to 31.2 in the poor trajectory group. For future perspective, the good group improved from 56.4 to 79.0, while the poor group increased from 39.3 to 57.2. Patients with human epidermal growth factor receptor 2-positive BC (adjusted odds ratio (aOR) = 0.57, 95% confidence interval (CI) 0.35-0.94, <i>p</i> = 0.028) and those with public health insurance (aOR = 0.41, 95% CI 0.16-0.90, <i>p</i> = 0.035) were less likely to belong to the poor trajectory group.</p><p><strong>Conclusion: </strong>A high proportion of YWBC experience a poor QoL trajectory over time, particularly in areas related to sexual health, future perspective, and hair loss.</p>\",\"PeriodicalId\":23053,\"journal\":{\"name\":\"Therapeutic Advances in Medical Oncology\",\"volume\":\"17 \",\"pages\":\"17588359251337493\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2025-05-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12084701/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Medical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/17588359251337493\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17588359251337493","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:患有乳腺癌(YWBC)的年轻女性通常接受强化治疗,这对她们的生活质量(QoL)产生了负面影响。然而,关于他们的生活质量如何变化的信息有限,因为大多数研究都集中在老年患者身上。目的:评估青壮年妇女生活质量的变化,确定受影响最大的生活质量领域,并确定与这些变化相关的因素。设计:Joven & Fuerte是一项多中心队列研究,研究对象为2014 - 2020年墨西哥新诊断为BC的年龄≥40岁的女性。方法:参与者在从入组到诊断后第5年的5个不同时间点完成欧洲癌症研究和治疗组织乳腺癌模块QLQ-BR23问卷。同时收集临床和治疗资料。采用基于组的多变量轨迹模型分析各生活质量域的纵向变化,并将患者分为适当的组。然后使用逻辑模型来确定变量和群体分类之间的关联。结果:共有477名女性(中位年龄:36岁;四分位数范围为32-38)。大多数人有公共健康保险(87%),诊断为II期(49%)或III期(39%)BC。两个轨迹组,即“好”和“差”,是根据QLQ-BR23分数确定的。大多数患者(n = 294, 62%)属于较差组。在良好组中,从基线到第5年,性享受得分保持稳定(51.4),而在较差组中,得分下降(51.0-37.3)。随着时间的推移,与脱发相关的痛苦程度有所下降,良好轨迹组的得分从36.3降至27.0,而不良轨迹组的得分从43.4降至31.2。展望未来,良好组从56.4上升到79.0,而较差组从39.3上升到57.2。人表皮生长因子受体2阳性BC患者(调整优势比(aOR) = 0.57, 95%可信区间(CI) 0.35-0.94, p = 0.028)和公共健康保险患者(aOR = 0.41, 95% CI 0.16-0.90, p = 0.035)不太可能属于不良预后组。结论:随着时间的推移,高比例的YWBC患者的生活质量轨迹较差,特别是在性健康、未来前景和脱发方面。
Evaluating changes in the breast cancer-related quality of life of young women with breast cancer: long-term results from a multicenter prospective cohort.
Background: Young women with breast cancer (YWBC) typically undergo intensive treatment that negatively impacts their quality of life (QoL). However, limited information is available on how their QoL changes, as most research has focused on older patients.
Objectives: To assess changes in QoL among YWBC, identify the most affected QoL domains, and identify the factors associated with these changes.
Design: Joven & Fuerte is a multicenter cohort of women aged ⩽40 in Mexico with newly diagnosed BC from 2014 to 2020.
Methods: Participants completed the European Organization for Research and Treatment of Cancer Breast Cancer module QLQ-BR23 questionnaire at five different time points from enrollment until year 5 postdiagnosis. Clinical and treatment data were also collected. Group-based multivariate trajectory modeling was used to analyze longitudinal changes across QoL domains and classify patients into appropriate groups. Logistic models were then employed to identify associations between variables and group classification.
Results: A total of 477 women (median age: 36 years; interquartile range 32-38) were included. Most had public health insurance (87%) and were diagnosed with stage II (49%) or III (39%) BC. Two trajectory groups, namely, "good" and "poor," were identified based on QLQ-BR23 scores. Most patients (n = 294, 62%) were in the poor group. In the good group, sexual enjoyment scores remained stable from baseline to year 5 (51.4), whereas those in the poor group decreased (51.0-37.3). Distress related to hair loss over time declined, with scores decreasing from 36.3 to 27.0 in the good trajectory group and from 43.4 to 31.2 in the poor trajectory group. For future perspective, the good group improved from 56.4 to 79.0, while the poor group increased from 39.3 to 57.2. Patients with human epidermal growth factor receptor 2-positive BC (adjusted odds ratio (aOR) = 0.57, 95% confidence interval (CI) 0.35-0.94, p = 0.028) and those with public health insurance (aOR = 0.41, 95% CI 0.16-0.90, p = 0.035) were less likely to belong to the poor trajectory group.
Conclusion: A high proportion of YWBC experience a poor QoL trajectory over time, particularly in areas related to sexual health, future perspective, and hair loss.
期刊介绍:
Therapeutic Advances in Medical Oncology is an open access, peer-reviewed journal delivering the highest quality articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in medical oncology, providing a forum in print and online for publishing the highest quality articles in this area. This journal is a member of the Committee on Publication Ethics (COPE).